Bg pattern

INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show translation

Introducción

Prospecto: Información para el paciente

Integrilin 0,75mg/ml solución para perfusión

eptifibatida

Lea todo el prospecto detenidamente antes de empezar a usar este medicamento, porque contiene información importante para usted.

  • Conserve este prospecto ya que puede tener que volver a leerlo.
  • Si tiene alguna duda, consulte a su médico, farmacéutico del hospital o enfermero.
  • Si experimenta efectos adversos, consulte a su médico, farmacéutico del hospital o enfermero, incluso si se trata de efectos adversos que no aparecen en este prospecto. Ver sección 4.

Contenido del prospecto

  1. Qué es Integrilin y para qué se utiliza
  2. Qué necesita saber antes de que le administren Integrilin
  3. Cómo usar Integrilin
  4. Posibles efectos adversos
  5. Conservación de Integrilin
  6. Contenido del envase e información adicional

1. Qué es Integrilin y para qué se utiliza

Integrilin es un inhibidor de la agregación plaquetaria. Esto significa que ayuda a prevenir la formación de coágulos sanguíneos.

Se utiliza en adultos con manifestación de insuficiencia coronaria grave definida como dolor torácico espontáneo y reciente con alteraciones electrocardiográficas o cambios biológicos. Se administra normalmente junto con aspirina y heparina no fraccionada.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. Qué necesita saber antes de que le administren Integrilin

No deben administrarleIntegrilin:

  • si es alérgico a la eptifibatida o a cualquiera de los demás componentes de este medicamento (incluidos en la sección 6)
  • si ha presentado recientemente una hemorragia de origen gástrico, intestinal, vesical o de otro órgano, por ejemplo, si se ha observado de forma anormal sangre en las heces o la orina (excepto la hemorragia menstrual) en los últimos 30 días
  • si ha padecido un accidente cerebrovascular dentro de los 30 días previos o cualquier accidente cerebrovascular hemorrágico (además, asegúrese de que su médico sepa si ha padecido alguna vez un accidente cerebrovascular)
  • si ha padecido un tumor cerebral o un proceso que afecte a los vasos sanguíneos del cerebro
  • si ha sido sometido a una operación importante o ha padecido una lesión grave durante las 6 semanas previas
  • si presenta o ha presentado problemas de hemorragias
  • si presenta o ha presentado problemas de la coagulación sanguínea o un recuento de plaquetas bajo.
  • si presenta o ha presentado hipertensión grave (tensión arterial alta)
  • si presenta o ha presentado problemas hepáticos o renales graves
  • si ha sido tratado con otro medicamento del mismo tipo que Integrilin.

Si ha presentado alguna de las situaciones anteriores, comuníquelo a su médico. Si tuviera alguna pregunta, consulte a su médico, farmacéutico del hospital o enfermero.

Tenga especial cuidado conIntegrilin:

  • Integrilin solamente se recomienda para su uso en pacientes adultos, hospitalizados en unidades de cuidados coronarios.
  • Integrilin no debe emplearse en niños o adolescentes menores de 18 años.
  • Antes y durante su tratamiento con Integrilin, se analizarán muestras de su sangre como una medida de seguridad para limitar la posibilidad de hemorragia inesperada.
  • Durante la utilización de Integrilin, usted será observado cuidadosamente en busca de signos de hemorragia inusual o inesperada.

Uso de Integrilin con otros medicamentos

Para evitar la posibilidad de interacciones con otros medicamentos informe a su médico, farmacéutico del hospital o enfermero si está utilizando, ha utilizado recientemente o podría tener que utilizar cualquier otro medicamento, incluso los adquiridos sin receta.

Especialmente:

  • diluyentes sanguíneos (anticoagulantes orales) o
  • fármacos que evitan la formación de coágulos sanguíneos, tales como warfarina, dipiridamol, ticlopidina, aspirina (excepto aquellos que pudiera recibir como parte del tratamiento con Integrilin).

Embarazo y lactancia

El uso de Integrilin no está normalmente recomendado durante el embarazo. Indíquele a su médico si está embarazada, cree que podría estar embarazada o tiene intención de quedarse embarazada. Su médico valorará si los beneficios del tratamiento con Integrilin para usted compensan los posibles riesgos para su bebé.

Si está dando el pecho a un bebé, la lactancia deberá interrumpirse durante el período de tratamiento.

Integrilin contiene sodio

  • Este medicamento contiene 161 mg de sodio (componente principal de la sal de mesa/para cocinar) en cada vial de 100 ml. Esto equivale al 8,1% de la ingesta diaria máxima de sodio recomendada para un adulto.

3. Cómo usar Integrilin

Integrilin se administra en vena mediante inyección directa seguida de una perfusión (solución gota a gota). La dosis administrada se basa en su peso. La dosis recomendada es de 180 microgramos/kg administrados en un bolo (inyección intravenosa rápida), seguido de una perfusión (solución gota a gota) de 2,0 microgramos/kg/minuto durante un máximo de 72 horas. Si tiene una enfermedad de riñón, la dosis para perfusión puede reducirse a 1,0 microgramo/kg/minuto.

Si se practica una intervención coronaria percutánea durante el tratamiento con Integrilin, la solución intravenosa podría continuarse durante un máximo de 96 horas.

Usted también deberá recibir algunas dosis de ácido acetilsalicílico (aspirina) y heparina (si no está contraindicado en su caso).

Si tiene cualquier otra duda sobre el uso de este producto, pregunte a su médico, farmacéutico del hospital o enfermero.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Posibles efectos adversos

Al igual que todos los medicamentos, este medicamento puede producir efectos adversos, aunque no todas las personas los sufran.

Efectos adversos muy frecuentes

Estos pueden afectar a más de 1 de cada 10 personas

  • hemorragia menor o mayor (por ejemplo sangre en la orina, en las heces, vómito con sangre o sangrado por la cirugía)
  • anemia (descenso en el número de células rojas o hematíes de la sangre).

Efectos adversos frecuentes

Estos pueden afectar hasta 1 de cada 10 personas

  • inflamación de una vena.

Efectos adversos poco frecuentes

Estos pueden afectar hasta 1 de cada 100 personas

  • descenso del número de plaquetas (células de la sangre que son necesarias para su coagulación)
  • disminución del flujo de sangre al cerebro.

Efectos adversos muy raros

Estos pueden afectar hasta 1 de cada 10.000 personas

  • sangrado grave (por ejemplo, sangrado en el interior del abdomen, el cerebro o los pulmones).
  • sangrado con desenlace fatal
  • disminución grave del número de plaquetas (células de la sangre que son necesarias para su coagulación)
  • erupción cutánea (tales como habones o ronchas)
  • reacción alérgica grave y repentina.

Si aprecia cualquier signo de hemorragia, dígaselo inmediatamente a su médico, farmacéutico del hospital o enfermero. Muy raramente, la hemorragia ha llegado a ser grave e incluso mortal. Las medidas de seguridad para evitar que esto ocurra incluyen análisis de sangre y un control minucioso de los profesionales sanitarios que le cuidan.

Si muestra los síntomas de una reacción alérgica grave o ronchas cutáneas, dígaselo inmediatamente a su médico, farmacéutico del hospital o enfermero.

Otros efectos que pueden aparecer en pacientes que necesitan este tipo de tratamiento incluyen aquellos relacionados con la condición para la que está siendo tratado, como latidos rápidos o irregulares del corazón, baja presión sanguínea, shock o paro cardiaco.

Comunicación de efectos adversos

Si experimenta cualquier tipo de efecto adverso, consulte a su médico, farmacéutico de hospital o enfermero, incluso si se trata de posibles efectos adversos que no aparecen en este prospecto. También puede comunicarlos directamente a través del sistema nacional de notificación incluido en el Apéndice V. Mediante la comunicación de efectos adversos usted puede contribuir a proporcionar más información sobre la seguridad de este medicamento.

5. Conservación de Integrilin

Mantener este medicamento fuera de la vista y del alcance de los niños.

No utilice este medicamento después de la fecha de caducidad (CAD) que aparece en el embalaje exterior y en el vial. La fecha de caducidad es el último día del mes que se indica.

Conservar en nevera (entre 2ºC y 8ºC).

Conservar el vial en el embalaje exterior para protegerlo de la luz. No obstante, durante la administración de la solución de Integrilin no se precisa protección frente a la luz.

Antes de su empleo, se debe examinar el contenido del vial.

No utilice Integrilin si se observan partículas o un cambio de color.

Una vez abierto, se debe tirar el medicamento no utilizado.

Los medicamentos no se deben tirar por los desagües ni a la basura. Pregunte a su farmacéutico cómo deshacerse de los envases y de los medicamentos que ya no necesita. De esta forma, ayudará a proteger el medio ambiente.

6. Contenido del envase e información adicional

Composición de Integrilin

  • El principio activo es eptifibatida. Cada ml de solución para perfusión contiene 0,75 mg de eptifibatida. Un vial de 100 ml de solución para perfusión contiene 75 mg de eptifibatida.
  • Los demás componentes son ácido cítrico monohidrato, hidróxido de sodio y agua para preparaciones inyectables.

Aspecto del producto y contenido del envase

Integrilin solución para perfusión: vial de 100 ml, envase con un vial.

La solución transparente, incolora está contenida en un vial de vidrio de 100 ml, cerrado con un tapón de goma de butilo y cápsula de aluminio de borde doblado.

Titular de la autorización de comercialización y responsable de la fabricación

Titular de la autorización de comercialización:

GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Irlanda

Responsable de la fabricación:

GlaxoSmithKline Manufacturing S.P.A., Strada Provinciale Asolana No. 90, San Polo di Torrile 43056, Parma, Italia

Pueden solicitar más información respecto a este medicamento dirigiéndose al representante local del titular de la autorización de comercialización.

België/Belgique/Belgien

GlaxoSmithKline Pharmaceuticals s.a./n.v.

Tél/Tel: + 32 (0) 10 85 52 00

Lietuva

GlaxoSmithKline (Ireland) Limited

Tel: +370 80000334

????????

GlaxoSmithKline (Ireland) Limited

???. +359 80018205

Luxembourg/Luxemburg

GlaxoSmithKline Pharmaceuticals s.a./n.v.

Belgique/Belgien

Tél/Tel: + 32 (0) 10 85 52 00

Ceská republika

GlaxoSmithKline s.r.o.

Tel: + 420 222 001 111

[email protected]

Magyarország

GlaxoSmithKline (Ireland) Limited

Tel.: +36 80088309

Danmark

GlaxoSmithKline Pharma A/S

Tlf: + 45 36 35 91 00

[email protected]

Malta

GlaxoSmithKline (Ireland) Limited

Tel: +356 80065004

Deutschland

GlaxoSmithKline GmbH & Co. KG

Tel.: + 49 (0)89 36044 8701

[email protected]

Nederland

GlaxoSmithKline BV

Tel: + 31 (0)33 2081100

Eesti

GlaxoSmithKline (Ireland) Limited

Tel: +372 8002640

Norge

GlaxoSmithKline AS

Tlf: + 47 22 70 20 00

Ελλ?δα

GlaxoSmithKline Μονοπρ?σωπη A.E.B.E.

Τηλ: + 30 210 68 82 100

Österreich

GlaxoSmithKline Pharma GmbH

Tel: + 43 (0)1 97075 0

[email protected]

España

GlaxoSmithKline, S.A.

Tel: + 34 900 202 700

[email protected]

Polska

GSK Services Sp. z o.o.

Tel.: + 48 (0)22 576 9000

France

Laboratoire GlaxoSmithKline

Tél.: + 33 (0)1 39 17 84 44

[email protected]

Portugal

GlaxoSmithKline – Produtos Farmacêuticos, Lda

Tel: + 351 21 412 95 00

[email protected]

Hrvatska

GlaxoSmithKline (Ireland) Limited

Tel: +385 800787089

România

GlaxoSmithKline (Ireland) Limited

Tel: +40 800672524

Ireland

GlaxoSmithKline (Ireland) Limited

Tel: + 353 (0)1 4955000

Slovenija

GlaxoSmithKline (Ireland) Limited

Tel: +386 80688869

Ísland

Vistor hf.

Sími: + 354 535 7000

Slovenská republika

GlaxoSmithKline (Ireland) Limited

Tel: +421 800500589

Italia

GlaxoSmithKline S.p.A.

Tel: + 39 (0)45 7741 111

Suomi/Finland

GlaxoSmithKline Oy

Puh/Tel: + 358 (0)10 30 30 30

[email protected]

Κ?προς

GlaxoSmithKline (Ireland) Limited

Τηλ: +357 80070017

Sverige

GlaxoSmithKline AB

Tel: + 46 (0)8 638 93 00

[email protected]

Latvija

GlaxoSmithKline (Ireland) Limited

Tel: +371 80205045

United Kingdom (Northern Ireland)

GlaxoSmithKline (Ireland) Limited

Tel: + 44 (0)800 221441

[email protected]

Fecha de la última revisión de este prospecto:

Otras fuentes de información

La información detallada de este medicamento está disponible en la página web de la Agencia Europea de Medicamentos: http://www.ema.europa.eu/

Online doctors for INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION

Discuss questions about INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
0.0 (11)
Doctor

Rita Isabel Calero Garcia

General medicine 2 years exp.

Dr. Rita Isabel Calero Garcia is a physician with extensive experience in emergency medical care, general medicine, and healthcare assistance in various clinical and out-of-hospital settings.

She currently works as a physician at the Canary Islands Emergency Service (Servicio de Urgencias Canario – SUC), where she is responsible for the assessment and care of patients in medical emergency situations, performing the initial diagnosis, patient stabilization, and coordination with hospital services when necessary.

She has also developed her professional activity within the Primary Care Management Service, providing consultations in general medicine. In this setting she is responsible for patient follow-up, management of acute and chronic conditions, as well as health promotion and disease prevention.

She has also worked as a physician in a mobile ICU unit, providing medical assistance in out-of-hospital emergencies, treating critical patients and participating in medicalized patient transport.

In addition, she has collaborated with the Red Cross, participating in healthcare support units, providing medical assistance at events and supporting emergency interventions.

Furthermore, she has provided medical services in the private sector with Salvaser, conducting clinical assessments of patients and providing healthcare services within private medical services.

0.0 (0)
Doctor

Joao Silva

General medicine 6 years exp.

Dr. João Silva is a physician with training and experience in the field of General and Family Medicine, dedicated to providing healthcare focused on the well-being and quality of life of his patients. Throughout his professional career, he has developed broad clinical competencies, striving to maintain a medical practice based on scientific evidence and continuous knowledge updates.

Between 2013 and 2019, he completed the Integrated Master's Degree in Medicine at the Abel Salazar Institute of Biomedical Sciences in Porto, where he acquired a solid academic and clinical education.

Subsequently, between January 2021 and December 2021, he completed the General Internship at the Entre Douro e Vouga Hospital Center in Santa Maria da Feira, where he had the opportunity to work in different hospital settings and deepen his competencies in several areas of medicine.

From January 2022 until March 2026, he works as a Resident Physician in General and Family Medicine at USF Salvador Machado in Oliveira de Azeméis, developing clinical activities in primary healthcare, follow-up of chronic patients, and health promotion in the community.

Complementing his medical training, Dr. João Silva also completed a Postgraduate Degree in Continuing and Palliative Care at CESPU, strengthening his preparation in the comprehensive approach to patient care, especially in situations requiring prolonged care and multidisciplinary support.

5.0 (53)
Doctor

Anna Biriukova

General medicine 6 years exp.

Dr Anna Biriukova is an internal medicine doctor with clinical experience in cardiology, endocrinology, and gastroenterology. She provides online consultations for adults, offering expert medical support for heart health, hormonal balance, digestive issues, and general internal medicine.

Cardiology – Diagnosis and treatment of:

  • High blood pressure, blood pressure fluctuations, and cardiovascular risk prevention.
  • Chest pain, shortness of breath, arrhythmias (tachycardia, bradycardia, palpitations).
  • Leg swelling, chronic fatigue, reduced exercise tolerance.
  • EKG interpretation, lipid profile evaluation, cardiovascular risk assessment (heart attack, stroke).
  • Post-COVID-19 cardiac monitoring and care.
Endocrinology – Diabetes, thyroid, metabolism:
  • Diagnosis and management of type 1 and type 2 diabetes, and prediabetes.
  • Individual treatment plans including oral medications and insulin therapy.
  • GLP-1 therapy– modern pharmacological treatment for weight management and diabetes control, including drug selection, monitoring, and safety follow-up.
  • Thyroid disorders – hypothyroidism, hyperthyroidism, autoimmune thyroid diseases (Hashimoto’s, Graves’ disease).
  • Metabolic syndrome – obesity, lipid disorders, insulin resistance.
Gastroenterology – Digestive health:
  • Abdominal pain, nausea, heartburn, gastroesophageal reflux (GERD).
  • Stomach and intestinal conditions: gastritis, irritable bowel syndrome (IBS), indigestion.
  • Management of chronic digestive disorders and interpretation of tests (endoscopy, ultrasound, labs).
General internal medicine and preventive care:
  • Respiratory infections – cough, colds, bronchitis.
  • Lab test analysis, therapy adjustments, medication management.
  • Adult vaccinations – planning, contraindications assessment.
  • Cancer prevention – screening strategies and risk assessment.
  • Holistic approach – symptom relief, complication prevention, and quality of life improvement.
Dr Biriukova combines internal medicine with specialist insight, offering clear explanations, personalised treatment plans, and comprehensive care tailored to each patient.
0.0 (15)
Doctor

Antonio Cayatte

General medicine 44 years exp.

Dr Antonio Cayatte is a physician in General and Acute Medicine with over 30 years of experience across clinical care, medical research, and education. He offers online consultations for adults with a wide range of symptoms, both acute and chronic. His clinical background includes: 

  • assessment of sudden or unclear symptoms
  • ongoing care for chronic conditions
  • follow-up after hospital discharge
  • interpretation of test results
  • medical support while abroad

Dr Cayatte earned his degree from the University of Lisbon and taught internal medicine at Boston University School of Medicine. He holds active medical registrations in both Portugal and the UK and is a Fellow of the American Heart Association. Consultations are available in English and Portuguese. Patients value his clarity, professionalism, and balanced approach to evidence-based care.

Dr. Antonio Cayatte provides comprehensive care for a broad spectrum of common health concerns, including:

  • Respiratory & ENT: acute bronchitis, concerns related to pneumonia, sinusitis, tonsillitis, ear infections, sore throat conditions, and allergic rhinitis
  • Eye Health: allergic and infectious conjunctivitis, as well as red or irritated eyes
  • Digestive & Urinary: gastroesophageal reflux disease (GERD), gastritis, urinary tract infections, and cystitis
  • Chronic Conditions: hypertension, elevated cholesterol, and structured weight management planning
0.0 (0)
Doctor

Sviatoslav Chekhun

Oncology 13 years exp.

Dr. Sviatoslav Chekhun is a medical oncologist with international clinical and research experience, specializing in modern medical oncology and a personalized approach to cancer treatment.

Currently (since 2025), he works as a Medical Oncologist at Institut Català d’Oncologia (Girona, Spain). Previously, he completed his residency in Medical Oncology and was involved in clinical research at Hospital Universitari Germans Trias i Pujol.

Dr. Chekhun has a strong academic and scientific background. He served as a lecturer in Internal Medicine at O.O. Bohomolets National Medical University and conducted research in experimental oncology at the R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology.

Earlier in his career, he worked as a medical oncologist at the Kyiv City Clinical Oncological Center and contributed to regulatory evaluation of medicinal products at the State Expert Center of the Ministry of Health of Ukraine.

When to consult Dr. Chekhun:

  •  for diagnosis or clarification of a cancer diagnosis
  •  to obtain a second opinion on an existing treatment plan 
  •  when you need a personalized treatment strategy 
  •  for interpretation of test results, CT, MRI, PET-CT, and biopsies 
  •  when choosing between treatment options (chemotherapy, targeted therapy, immunotherapy) 
  •  in case of doubts about treatment strategy or disease progression 

Consultation format

Dr. Chekhun provides online consultations, where you can receive:

  •  expert second opinion 
  •  detailed case review 
  •  recommendations based on current international treatment guidelines 
  •  personalized treatment and follow-up plan 

Important:
Prescription and monitoring of medications must be carried out by your treating physician in an in-person (offline) setting. An online consultation does not replace a face-to-face visit but helps you make more informed decisions about your treatment.

Dr. Sviatoslav Chekhun combines clinical practice, research, and international experience, enabling him to provide patients with modern, evidence-based approaches in oncology.

5.0 (194)
Doctor

Yevgen Yakovenko

General surgery 12 years exp.

Dr. Yevgen Yakovenko is a licensed surgeon and general practitioner in Spain and Germany. He specialises in general, paediatric, and oncological surgery, internal medicine, and pain management. He offers online consultations for adults and children, combining surgical precision with therapeutic support. Dr Yakovenko works with patients across different countries and provides care in Ukrainian, Russian, English, and Spanish.

Areas of medical expertise:

  • Acute and chronic pain: headaches, muscle and joint pain, back pain, abdominal pain, postoperative pain. Identifying the cause, selecting treatment, and creating a care plan.
  • Internal medicine: heart, lungs, gastrointestinal tract, urinary system. Management of chronic conditions, symptom control, second opinions.
  • Pre- and postoperative care: risk assessment, decision-making support, follow-up after surgery, rehabilitation strategies.
  • General and paediatric surgery: hernias, appendicitis, congenital conditions, both planned and urgent surgeries.
  • Injuries and trauma: bruises, fractures, sprains, soft tissue damage, wound care, dressing, referral when in-person care is required.
  • Oncological surgery: diagnosis review, treatment planning, and long-term follow-up.
  • Obesity treatment and weight management: a medical approach to weight loss, including assessment of underlying causes, evaluation of comorbidities, development of a personalised plan (nutrition, physical activity, pharmacotherapy if needed), and ongoing progress monitoring.
  • Imaging interpretation: analysis of ultrasound, CT, MRI, and X-ray results, surgical planning based on imaging data.
  • Second opinions and medical navigation: clarifying diagnoses, reviewing current treatment plans, helping patients choose the best course of action.

Experience and qualifications:

  • 12+ years of clinical experience in university hospitals in Germany and Spain.
  • International education: Ukraine – Germany – Spain.
  • Member of the German Society of Surgeons (BDC).
  • Certified in radiological diagnostics and robotic surgery.
  • Active participant in international medical conferences and research.

Dr Yakovenko explains complex topics in a clear, accessible way. He works collaboratively with patients to analyse health issues and make evidence-based decisions. His approach is grounded in clinical excellence, scientific accuracy, and respect for each individual.

If you are unsure about a diagnosis, preparing for surgery, or want to discuss your test results – Dr Yakovenko will help you evaluate your options and move forward with confidence.

Get INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION Prescription Online

1

Fill in a 2-min form

Tell us your symptoms, history, and what medicine you're requesting.

2

Pick a doctor or let us assign

Choose a specialist or we'll match you with the next available doctor.

3

Doctor reviews your case

Usually within 30 minutes. They may ask follow-up questions via chat.

4

Collect from any pharmacy

Electronic prescription sent to your email — valid across Spain.

Frequently Asked Questions

Is a prescription required for INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION?

INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.

What is the active substance in INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION?

The active ingredient in INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION is eptifibatide. This information helps identify medicines with the same composition but different brand names.

Who manufactures INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION?

INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION is manufactured by Glaxosmithkline (Ireland) Limited. Pharmacy brands and packaging may differ depending on the distributor.

Which doctors can assess the use of INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION online?

Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.

How to buy INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION in Spain?

Spain has a well-developed healthcare infrastructure across major cities such as Madrid, Barcelona, Valencia, and Seville. Pharmacies are widely available and operate under strict regulations, ensuring access to prescribed medications.

You can buy INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION in Madrid, Barcelona, Seville, or Valencia at any local pharmacy with a valid prescription.

To obtain a prescription, you can use Oladoctor:

What are the alternatives to INTEGRILIN 0.75 mg/ml SOLUTION FOR INFUSION?

Other medicines with the same active substance (eptifibatide) include EPTIFIBATIDE ACCORD 0.75 mg/mL SOLUTION FOR INFUSION, EPTIFIBATIDE ACCORD 2 mg/ml INJECTABLE SOLUTION, INTEGRILIN 2 mg/ml INJECTABLE SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.

bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media